[go: up one dir, main page]

MX2019010568A - Nueva forma farmaceutica. - Google Patents

Nueva forma farmaceutica.

Info

Publication number
MX2019010568A
MX2019010568A MX2019010568A MX2019010568A MX2019010568A MX 2019010568 A MX2019010568 A MX 2019010568A MX 2019010568 A MX2019010568 A MX 2019010568A MX 2019010568 A MX2019010568 A MX 2019010568A MX 2019010568 A MX2019010568 A MX 2019010568A
Authority
MX
Mexico
Prior art keywords
release
pharmaceutical form
release layer
delayed
ifa
Prior art date
Application number
MX2019010568A
Other languages
English (en)
Other versions
MX383980B (es
Inventor
Scheer Mathias
Rey Helene
Original Assignee
Develco Pharma Schweiz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Develco Pharma Schweiz Ag filed Critical Develco Pharma Schweiz Ag
Publication of MX2019010568A publication Critical patent/MX2019010568A/es
Publication of MX383980B publication Critical patent/MX383980B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención refiere a una forma farmacéutica sólida oral que tiene un orden novedoso y bien definido de recubrimientos específicos que permiten una liberación controlada y muy bien definida de al menos un ingrediente farmacéutico activo (IFA), con una gran variedad de usos potenciales. En particular, la forma farmacéutica de la presente invención comprende un núcleo activo de liberación inmediata, una primera capa de liberación retardada que comprende un recubrimiento entérico, una segunda capa de liberación prolongada que comprende un polímero retardante, y una tercera capa de liberación inmediata que comprende un ingrediente farmacéutico activo. Así, la forma farmacéutica sólida oral se caracteriza por un perfil de liberación bimodal del/de los IFA, con una segunda liberación retardada mucho menos variable que la que se obtiene con las composiciones farmacéuticas conocidas en la técnica, lo que permite la aplicación de diferentes IFA o combinaciones de estos para diversas indicaciones.
MX2019010568A 2017-03-09 2018-03-08 Nueva forma farmacéutica. MX383980B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17160206.3A EP3372225A1 (en) 2017-03-09 2017-03-09 Novel dosage form
PCT/EP2018/055847 WO2018162688A1 (en) 2017-03-09 2018-03-08 Novel dosage form

Publications (2)

Publication Number Publication Date
MX2019010568A true MX2019010568A (es) 2019-12-19
MX383980B MX383980B (es) 2025-03-14

Family

ID=58266457

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019010568A MX383980B (es) 2017-03-09 2018-03-08 Nueva forma farmacéutica.

Country Status (12)

Country Link
US (1) US20210059944A1 (es)
EP (1) EP3372225A1 (es)
CN (1) CN110381926A (es)
AU (1) AU2018232854B2 (es)
BR (1) BR112019018612A2 (es)
CA (1) CA3053696A1 (es)
IL (1) IL269169B2 (es)
MX (1) MX383980B (es)
MY (1) MY205603A (es)
SG (1) SG11201907539TA (es)
WO (1) WO2018162688A1 (es)
ZA (1) ZA201905664B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11241391B2 (en) 2011-03-23 2022-02-08 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
AU2020212036B2 (en) * 2019-01-25 2025-08-28 Ironshore Pharmaceuticals & Development, Inc. Methylphenidate compositions for treatment of attention deficit hyperactivity disorder
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US6322819B1 (en) * 1998-10-21 2001-11-27 Shire Laboratories, Inc. Oral pulsed dose drug delivery system
US7083808B2 (en) * 1998-12-17 2006-08-01 Euro-Celtique S.A. Controlled/modified release oral methylphenidate formulations
US6673367B1 (en) * 1998-12-17 2004-01-06 Euro-Celtique, S.A. Controlled/modified release oral methylphenidate formulations
US6419960B1 (en) * 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
US6344215B1 (en) * 2000-10-27 2002-02-05 Eurand America, Inc. Methylphenidate modified release formulations
US8846100B2 (en) * 2006-05-12 2014-09-30 Shire Llc Controlled dose drug delivery system
WO2008140459A1 (en) * 2007-05-16 2008-11-20 Fmc Corporation Solid form
WO2011020032A2 (en) * 2009-08-13 2011-02-17 Kudco Ireland, Ltd. Pharmaceutical dosage form
AR096438A1 (es) * 2013-05-29 2015-12-30 Gruenenthal Gmbh Forma de dosificación resistente al uso indebido con perfil de liberación bimodal, proceso

Also Published As

Publication number Publication date
MX383980B (es) 2025-03-14
SG11201907539TA (en) 2019-09-27
AU2018232854B2 (en) 2024-04-04
CN110381926A (zh) 2019-10-25
AU2018232854A1 (en) 2019-09-12
ZA201905664B (en) 2024-01-31
IL269169B2 (en) 2025-07-01
CA3053696A1 (en) 2018-09-13
BR112019018612A2 (pt) 2020-04-07
WO2018162688A1 (en) 2018-09-13
EP3372225A1 (en) 2018-09-12
US20210059944A1 (en) 2021-03-04
MY205603A (en) 2024-10-29
IL269169B1 (en) 2025-03-01
IL269169A (en) 2019-11-28

Similar Documents

Publication Publication Date Title
DK3826632T3 (da) Terapeutiske sammensætninger, der omfatter deutererede eller delvist deutererede n,n-dimethyltryptaminforbindelser
CL2017003089A1 (es) Formas de dosificación sólidas de palbociclib
SV2018005619A (es) Composiciones de oligonucleotidos y metodos de los mismos
CO2018005369A2 (es) Inhibidores triazol de acc y usos de los mismos
EP3612132A4 (en) MANUFACTURING OF DENTAL APPLIANCES
IL261249B1 (en) Dosage preparations containing Bruton's tyrosine kinase inhibitor
MX2017016509A (es) Particulas de dimetilfumarato y composiciones farmaceuticas de estas.
MX2016014320A (es) Composiciones de suspension de liberacion prolongada.
MX374012B (es) Formas solidas cristialinas de 6-carboxi-2-(3,5-diclorofenil)-benzoxazol.
CL2018001686A1 (es) Métodos y composiciones particularmente para el tratamiento del trastorno por déficit de atención (divisional solicitud 201701026)
WO2015011694A3 (en) Isotopologues of smad7 antisense oligonucleotides
CL2017002214A1 (es) Formulación de combinación de tesofensina y betabloqueante
MX2020006521A (es) Composicion para productos oftalmologicos.
MX2019010568A (es) Nueva forma farmaceutica.
EP3682489A4 (en) MANUFACTURING OF STACKED PEROVSKITE STRUCTURES
EA201691924A1 (ru) Фармацевтические композиции
BR112019001158A2 (pt) formas de succinato e composições de inibidores da tirosina quinase de bruton
EP3646855C0 (en) COMPOSITION FOR SOLID PREPARATION FOR ORAL USE COMPRISING A PROTON PUMP INHIBITOR, SOLID PREPARATION FOR ORAL USE COMPRISING SAME, AND METHOD FOR PREPARING SAME
BR112017019750A2 (pt) processo para preparação de uma forma cristalina de menaquinol, forma cristalina de menaquinol, processo para preparação de uma forma sólida do menaquinol, composição farmacêutica ou nutracêutica e uso da forma cristalina de menaquinol
CY1125399T1 (el) Διαρυλικες συνθεσεις και μεθοδοι για τη διαμορφωση ενος καταρρακτη κινασης
JP2020506196A5 (ja) テビペネムピボキシル結晶形、それを含む組成物、製造方法、および使用方法
EP3870099A4 (en) ANCHOR WITH HEALING CHAMBERS
AR108616A1 (es) Formulación combinada de tres compuestos antivirales
MX2020004202A (es) Fenil sulfonil fenil triazol tionas sustituidas y usos de las mismas.
CL2018000308A1 (es) Composiciones en microcápsulas que comprenden pirimetanilo